𝐔𝐧𝐩𝐚𝐜𝐤𝐢𝐧𝐠 𝐀𝐛𝐛𝐨𝐭𝐭’𝐬 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 𝐒𝐭𝐫𝐞𝐚𝐦𝐬

Historically, Abbott reported its revenue under two main categories, namely:

1- Diversified Medical Products, 2- Research-based Pharmaceutical Companies.

A significant milestone occurred in 2013, when Abbott split into two independent companies:

• Abbott (focusing on medical devices, diagnostics, and nutrition),
• AbbVie (concentrating on pharmaceuticals).

Since the split, Abbott and AbbVie have both thrived in their respective arenas, benefiting from a more focused strategy.

Today, under CEO Robert Ford’s leadership, Abbott generates roughly $42 billion in annual revenue, distributed across its four key segments:

1- Medical Devices (45%), 2- Diagnostics (22%), 3- Nutritional Products (20%), 4- Pharmaceutical Products (12%).

Under Lisa Earnhardt’s leadership, Abbott’s Medical Devices, the company’s largest segment, generates approximately $19 billion in annual revenue, with the following breakdown:

• Diabetes Care (36%),
• Vascular (15%),
• Electrophysiology (13%),
• Rhythm Management (13%),
• Structural Heart (12%),
• Heart Failure (7%),
• Neuromodulation (5%).

Under Lou Morrone’s leadership, Abbott’s Diagnostics, the company’s 2nd largest segment, generates $9.3B in annual revenue, with the following breakdown:

• Core Laboratory (56%),
• Rapid Diagnostics (32%),
• Point of Care (6%),
• Molecular (5%).

Nutritional products under Daniel Salvadori’s leadership generate $8.4B in annual revenue, with the following breakdown:

• Adult Nutritionals (52%),
• Pediatric Nutritionals (48%).

And Pharmaceutical products generate $5.2B in annual revenue, with the following breakdown:

• Key Emerging Markets (74%),
• Other (36%).

Today, Abbott stands as the world’s most valuable medical device company, with a market capitalization exceeding $200 billion and a global workforce of more than 110,000.

Views are my own. Content is all public data intended for educational purposes, not financial advice. I encourage readers to do their research. Visualization is done with PlotSet.